Advanced Vaginal Adenocarcinoma: Clinical Trials

1 trial for Advanced Vaginal Adenocarcinoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting. 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 31Active not recruiting 1

Follow Advanced Vaginal Adenocarcinoma: new trials by email Literature Review of Advanced Vaginal Adenocarcinoma trials Research Report on Advanced Vaginal Adenocarcinoma

Trials (filtered) newest first · largest first

All 1 trial

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers
Brachytherapy, Cisplatin, External Beam Radiation Therapy - Advanced Vaginal Adenocarcinoma, Advanced Vaginal Adenosquamous Carcinoma
Phase 3Active not recruitingNational Cancer Institute (NCI)4502016-05-102026-10-22

Narrower conditions

Uterine Cervical Neoplasms (1)  ·  Vaginal Neoplasms (1)

Broader conditions

Female Urogenital Diseases (1)  ·  Female Urogenital Diseases and Pregnancy Complications (1)  ·  Genital Diseases (1)  ·  Genital Diseases, Female (1)  ·  Genital Neoplasms, Female (1)  ·  Neoplasms (1)  ·  Neoplasms by Site (1)  ·  Urogenital Diseases (1)  ·  Urogenital Neoplasms (1)  ·  Uterine Cervical Diseases (1)  ·  Uterine Diseases (1)  ·  Uterine Neoplasms (1)  ·  Vaginal Diseases (1)

Interventions

1,2-diaminocyclohexaneplatinum II citrate (1)  ·  3-aminopyridine-2-carboxaldehyde thiosemicarbazone (1)  ·  Brachytherapy (1)  ·  Cisplatin (1)  ·  Congresses as Topic (1)  ·  Platinum (1)  ·  Radiation (1)  ·  Radiotherapy (1)  ·  Radiotherapy, Intensity-Modulated (1)

Sponsors

National Cancer Institute (NCI) (1)

Countries

Canada (1)  ·  Puerto Rico (1)  ·  United States (1)

Top investigators

Charles A Leath (1)

Results publications

PMID 29868473, PMID 31681600

NIH funding

U10CA180868 (1)